{
  "schemaVersion": 2,
  "eyebrow": "Hepatology",
  "title": "Primary Sclerosing Cholangitis",
  "summary": "Primary sclerosing cholangitis requires cholangiographic confirmation, exclusion of secondary causes, systematic evaluation for inflammatory bowel disease, and surveillance for hepatobiliary and colorectal malignancy. No drug has established disease-modifying benefit; management centers on complications, selected biliary intervention, and timely transplant referral.",
  "seoDescription": "Point-of-care review of primary sclerosing cholangitis diagnosis, cancer surveillance, biliary stricture management, IBD assessment, and transplant referral.",
  "clinicalQuestion": "How should clinicians diagnose, monitor, and manage complications and malignancy risk in primary sclerosing cholangitis?",
  "specialty": "Hepatology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "primary sclerosing cholangitis",
    "PSC",
    "MRCP",
    "cholangiocarcinoma surveillance",
    "dominant stricture",
    "PSC inflammatory bowel disease",
    "liver transplantation"
  ],
  "keyTakeaways": [
    "Suspect PSC with cholestatic liver injury; MRCP is the preferred noninvasive cholangiographic test, while ERCP is generally reserved for unresolved diagnostic questions or therapeutic evaluation of a clinically relevant stricture. [11][21]",
    "Assess every patient with PSC for concomitant IBD, including diagnostic colonoscopy when IBD is not already known; PSC is frequently associated with IBD, predominantly ulcerative colitis. [21]",
    "There is no established disease-modifying pharmacotherapy for PSC; management prioritizes symptom control, treatment of biliary and cirrhotic complications, malignancy surveillance, clinical trials, and transplant referral when indicated. [13][19][21]",
    "New or worsening jaundice, pruritus, cholangitis, biochemical deterioration, or a concerning stricture should trigger evaluation for obstruction and cholangiocarcinoma rather than attribution to PSC progression alone. [11][23]",
    "Liver transplantation is appropriate for decompensated cirrhosis and may be considered for recurrent bacterial cholangitis, severe refractory pruritus or jaundice, high-grade biliary dysplasia, selected hepatocellular carcinoma, and carefully selected hilar cholangiocarcinoma. [16][21]"
  ],
  "sections": [
    {
      "id": "diagnostic-approach",
      "eyebrow": "Diagnosis",
      "heading": "Confirm PSC and exclude mimics",
      "intro": "The central diagnostic decision is whether cholangiographic abnormalities represent primary rather than secondary sclerosing cholangitis.",
      "paragraphs": [
        "PSC should be considered with a cholestatic biochemical pattern, including elevated alkaline phosphatase, gamma-glutamyltransferase, or bilirubin, with or without symptoms. The defining clinical framework combines cholestatic liver biochemistry with multifocal biliary stricturing on cholangiography. [12][21]",
        "MRCP is generally the first cholangiographic study because it noninvasively evaluates intrahepatic and extrahepatic ducts, including ducts proximal to severe stenoses. Reported MRCP sensitivity and specificity for PSC are 85% to 88% and 92% to 97%, respectively; subtle early disease can be missed, and cirrhosis can distort ducts and mimic PSC. [11]",
        "ERCP is not a routine diagnostic substitute for MRCP because it is invasive, but it is appropriate when MRCP is nondiagnostic despite persistent clinical suspicion or when a stricture requires endoscopic assessment or therapy. ERCP also enables tissue-directed evaluation when malignancy is a concern. [11]"
      ],
      "bullets": [
        "Review the clinical context for secondary sclerosing cholangitis, including infection, neoplasia, or other obstructive and inflammatory biliary disorders before assigning a primary diagnosis. [20]",
        "Use liver biopsy selectively: sampled large-duct PSC can yield nonspecific portal inflammation and fibrosis, and classic duct-centered pathology may not be present in a limited specimen. [20]",
        "Obtain a diagnostic colonoscopy to evaluate for occult IBD when it is not already established. Approximately 68% of patients with PSC have IBD in population-based data, most commonly ulcerative colitis. [21]"
      ],
      "subsections": [],
      "table": {
        "caption": "Testing decisions in suspected or established PSC. [11][20][21]",
        "columns": [
          "Clinical situation",
          "Preferred next evaluation",
          "Interpretation or action"
        ],
        "rows": [
          [
            "Cholestatic liver tests with suspected PSC",
            "MRCP [11][21]",
            "Look for intrahepatic and/or extrahepatic multifocal stricturing; assess alternative structural explanations. [11][12]"
          ],
          [
            "Persistent suspicion with nondiagnostic MRCP",
            "Consider ERCP and selected liver biopsy [11][20]",
            "ERCP can clarify ductal anatomy; biopsy may support small-duct disease or evaluate competing liver disease, but may be nonspecific. [11][20]"
          ],
          [
            "PSC newly diagnosed without known IBD",
            "Diagnostic colonoscopy [21]",
            "Identify concomitant IBD, which materially affects colorectal cancer risk management. [21]"
          ],
          [
            "New jaundice, worsening cholestasis, cholangitis, or concerning imaging",
            "MRI/MRCP followed by targeted ERCP evaluation when indicated [11][23]",
            "Evaluate for a clinically important stricture and cholangiocarcinoma rather than presuming uncomplicated PSC progression. [11][23]"
          ]
        ]
      }
    },
    {
      "id": "disease-course-and-risk",
      "eyebrow": "Prognosis",
      "heading": "Risk is driven by progressive biliary injury and malignancy",
      "intro": "Prognosis is heterogeneous, but progressive liver disease and hepatobiliary malignancy determine major outcomes.",
      "paragraphs": [
        "PSC is a chronic fibroinflammatory cholangiopathy that can progress to biliary cirrhosis, portal-hypertensive complications, and liver failure. A review of PSC natural history reported median transplant-free survival of approximately 15 years, although individual trajectories vary substantially. [13]",
        "Cholangiocarcinoma is a defining competing risk. Published estimates in the supplied literature place lifetime cholangiocarcinoma risk at approximately 10% to 15%, although broader estimates of 9% to 31% have also been reported. [10][11] This variation underscores uncertainty in counseling an individual patient, but supports a low threshold to investigate a new obstructive or constitutional change.",
        "Gallbladder cancer risk is also increased. Reported prevalence estimates range from 2.5% to 3.5%, with substantially higher estimates in some series; prognosis after gallbladder cancer diagnosis is poor. [23]"
      ],
      "bullets": [
        "Do not use carbohydrate antigen 19-9 alone to diagnose or screen for cholangiocarcinoma: up to 33% of patients with PSC can have an elevated value without cholangiocarcinoma or another identified cause. [23]",
        "When MRI/MRCP identifies a suspicious stricture or mass, CA 19-9 may complement imaging but should not replace diagnostic evaluation. [23]",
        "Discuss early transplant-center involvement as complications emerge; transplantation offers excellent post-transplant outcomes, with generally greater than 85% five-year survival reported by AASLD educational material. [21]"
      ],
      "subsections": [],
      "table": {
        "caption": "Complications that should change evaluation or referral urgency. [16][21][23]",
        "columns": [
          "Finding",
          "Clinical concern",
          "Action supported by available evidence"
        ],
        "rows": [
          [
            "New or progressive jaundice, pruritus, or cholangitis",
            "Obstructive stricture or cholangiocarcinoma [11][23]",
            "Reassess with biliary imaging and use ERCP selectively for further evaluation or therapy. [11]"
          ],
          [
            "Recurrent bacterial cholangitis",
            "High morbidity and transplant indication [16][21]",
            "Refer to a transplant center while addressing biliary obstruction and infection. [16][21]"
          ],
          [
            "Decompensated cirrhosis or portal hypertension",
            "End-stage liver disease [16][21]",
            "Evaluate for liver transplantation. [16][21]"
          ],
          [
            "High-grade biliary dysplasia",
            "Advanced neoplastic risk [16][21]",
            "Discuss transplantation in a multidisciplinary hepatology and transplant setting. [16][21]"
          ]
        ]
      }
    },
    {
      "id": "management",
      "eyebrow": "Management",
      "heading": "Treat complications; do not overstate medical therapy",
      "intro": "No pharmacologic treatment in the supplied evidence has established disease-modifying benefit in PSC.",
      "paragraphs": [
        "Effective pharmacotherapy for PSC has not been established, and current educational reviews emphasize that no medical therapy has been shown to alter disease progression. Therefore, treatment should be directed at symptoms, bacterial cholangitis, biliary obstruction, portal-hypertensive and cirrhotic complications, nutritional consequences of cholestasis when present, and transplant candidacy. [13][19][21]",
        "Endoscopic intervention is most relevant when a clinically significant biliary stricture is suspected because of worsening cholestasis, jaundice, pruritus, cholangitis, or concern for malignancy. ERCP can define the lesion, facilitate directed diagnostic assessment, and permit nonoperative dilation of dominant strictures. [11][22]",
        "Refer patients with advanced disease to a transplant center before a crisis-driven evaluation. In addition to decompensated cirrhosis, recognized PSC-specific reasons to consider transplantation include recurrent bacterial cholangitis, intractable pruritus, severe jaundice, and high-grade biliary dysplasia. [16][21]"
      ],
      "bullets": [
        "Offer clinical-trial consideration when feasible because investigational therapies remain important in a disease without proven disease-modifying medical treatment. [19]",
        "Avoid labeling bile acid agents or immunosuppressive therapy as standard PSC treatment on the basis of the supplied evidence; no source provided supports a specific dose, efficacy threshold, or routine disease-modifying regimen.",
        "In patients with suspected PSC-autoimmune hepatitis overlap or another competing immune-mediated liver disease, pursue disease-specific diagnostic clarification rather than treating typical large-duct PSC empirically as autoimmune hepatitis. [20][24]"
      ],
      "subsections": [
        {
          "heading": "Transplant and cancer-directed pathways",
          "paragraphs": [
            "Liver transplantation is the only curative therapy for advanced PSC in the supplied evidence. For selected hilar cholangiocarcinoma, U.S. transplantation may be considered when tumor diameter is less than 3 cm, there is no lymph-node or distant metastasis, and chemoradiotherapy has been given. [16][19]"
          ],
          "bullets": [
            "Multidisciplinary assessment is essential when imaging or endoscopic evaluation raises concern for cholangiocarcinoma because resection, oncologic therapy, and transplant eligibility are stage-dependent. [16][23]"
          ]
        }
      ],
      "table": {
        "caption": "Management priorities by clinical problem. [11][16][19][21][22]",
        "columns": [
          "Problem",
          "Management focus",
          "Important limitation"
        ],
        "rows": [
          [
            "Stable PSC without decompensation",
            "Surveillance, IBD assessment, complication monitoring, and clinical-trial consideration [19][21]",
            "No established disease-modifying medication is supported by the supplied evidence. [13][19]"
          ],
          [
            "Suspected dominant or clinically relevant stricture",
            "MRCP-based reassessment and selective ERCP for evaluation, sampling, or endoscopic treatment [11][22]",
            "A stricture may reflect benign PSC progression or malignancy; evaluate for cholangiocarcinoma. [11][23]"
          ],
          [
            "Recurrent bacterial cholangitis or refractory cholestatic symptoms",
            "Treat acute complications and refer for transplant assessment [16][21]",
            "These are PSC-specific transplant considerations even without conventional decompensation alone. [16][21]"
          ],
          [
            "Decompensated cirrhosis",
            "Liver transplantation evaluation [16][21]",
            "Disease-specific drug therapy does not replace definitive advanced-liver-disease management. [19][21]"
          ]
        ]
      }
    },
    {
      "id": "surveillance-and-follow-up",
      "eyebrow": "Longitudinal care",
      "heading": "Surveillance should integrate biliary cancer and colonic risk",
      "intro": "PSC follow-up should be structured around changing symptoms, cholestatic tests, biliary imaging findings, and IBD status.",
      "paragraphs": [
        "Surveillance is justified by the substantial risk of cholangiocarcinoma and increased gallbladder cancer risk, but the supplied sources do not provide a single U.S. society-endorsed interval or a fully specified surveillance protocol. MRI/MRCP is central to evaluating concerning strictures or masses, and CA 19-9 is best interpreted as an adjunct because isolated elevation lacks sufficient specificity. [23]",
        "Colonoscopy at PSC diagnosis is important to identify occult IBD. Continued colorectal cancer prevention should then be coordinated with gastroenterology using the patient’s IBD phenotype and current guideline-based surveillance plan; exact U.S. surveillance intervals are not supplied in the source set. [21]",
        "At each follow-up, reassess for symptoms that indicate obstruction, infection, cancer, or hepatic decompensation: jaundice, escalating pruritus, fever or recurrent cholangitis, abdominal pain, weight loss, ascites, variceal bleeding, or encephalopathy. These changes should prompt expedited diagnostic reassessment rather than routine observation. [12][16][21][23]"
      ],
      "bullets": [
        "Document whether IBD is present and coordinate hepatology-gastroenterology care; PSC-associated IBD can be clinically silent at liver diagnosis. [21]",
        "Interpret a rising or elevated CA 19-9 in clinical context and alongside imaging, not as a stand-alone cancer diagnosis. [23]",
        "Use transplant referral proactively for recurrent cholangitis, severe pruritus or jaundice, high-grade biliary dysplasia, or decompensated cirrhosis. [16][21]"
      ],
      "subsections": [],
      "table": {
        "caption": "Longitudinal triggers for escalation in PSC. [16][21][23]",
        "columns": [
          "Follow-up change",
          "Why it matters",
          "Next clinical step"
        ],
        "rows": [
          [
            "Worsening bilirubin or cholestatic tests with symptoms",
            "May indicate obstruction, a relevant stricture, or malignancy [11][23]",
            "Obtain prompt biliary reassessment; consider ERCP based on imaging and clinical findings. [11]"
          ],
          [
            "Elevated CA 19-9",
            "False-positive elevation is common in PSC [23]",
            "Interpret with MRI/MRCP and the full clinical presentation. [23]"
          ],
          [
            "First recognition of PSC",
            "High prevalence of associated IBD [21]",
            "Perform diagnostic colonoscopy if IBD status is unknown. [21]"
          ],
          [
            "Recurrent cholangitis or refractory pruritus",
            "May establish transplant need despite absence of classic decompensation [16][21]",
            "Refer to a transplant center. [16][21]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "Is ERCP required to diagnose primary sclerosing cholangitis?",
      "answer": "No. MRCP is generally the preferred initial cholangiographic study because it is noninvasive and visualizes ducts proximal to severe stenoses. Reserve ERCP for nondiagnostic MRCP with persistent suspicion or when a stricture needs diagnostic or therapeutic endoscopic assessment. [11]"
    },
    {
      "question": "Should all patients with PSC undergo colonoscopy?",
      "answer": "Patients without known IBD should undergo diagnostic colonoscopy because PSC frequently coexists with IBD; AASLD educational material cites an approximately 68% prevalence, predominantly ulcerative colitis. [21]"
    },
    {
      "question": "Does an elevated CA 19-9 diagnose cholangiocarcinoma in PSC?",
      "answer": "No. Up to 33% of patients with PSC may have elevated CA 19-9 without cholangiocarcinoma or another identified cause. Use it only as an adjunct to imaging and clinical evaluation of a suspicious stricture or mass. [23]"
    },
    {
      "question": "What are PSC-specific indications for liver transplantation?",
      "answer": "In addition to decompensated cirrhosis, transplantation may be considered for recurrent bacterial cholangitis, severe refractory pruritus or jaundice, high-grade biliary dysplasia, and selected cases of hilar cholangiocarcinoma. [16][21]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "[PDF] CENTER FOR DRUG EVALUATION AND RESEARCH",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203214Orig1s018.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 2,
      "title": "Pharmacokinetics in Patients with Impaired Hepatic Function",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/71311/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 3,
      "title": "Search Orphan Drug Designations and Approvals",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=821121",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 4,
      "title": "219488Orig1s000 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/219488Orig1s000MultidisciplineR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 5,
      "title": "220295Orig1s000 INTEGRATED REVIEW - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220295Orig1s000IntegratedR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 6,
      "title": "September 13, 2024 Gastrointestinal Drugs Advisory ...",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/183843/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 7,
      "title": "Ocaliva® (Obeticholic Acid, OCA) ...",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/181819/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 8,
      "title": "Office of Immunology and Inflammation - Division of Hepatology and Nutrition (DHN) | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/about-fda/cder-offices-and-divisions/office-immunology-and-inflammation-division-hepatology-and-nutrition-dhn",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 9,
      "title": "EASL Clinical Practice Guidelines on sclerosing cholangitis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0168827822003269",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 10,
      "title": "Surgical Treatment of Primary Sclerosing Cholangitis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/B9780323402323001175",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 11,
      "title": "Primary Sclerosing Cholangitis - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/primary-sclerosing-cholangitis",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 12,
      "title": "Primary sclerosing cholangitis – a comprehensive review",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0168827817321967",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 13,
      "title": "Primary sclerosing cholangitis: A review and update",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6028044",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 14,
      "title": "Clinical guidelines for primary sclerosing cholangitis 2017",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8930933",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 15,
      "title": "The 2024 diagnostic criteria for primary sclerosing cholangitis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12450801",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 16,
      "title": "Primary Sclerosing Cholangitis: Diagnosis, Management, and ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12897808",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Study Details | NCT05618145 |  | ClinicalTrials.gov",
      "detail": "clinicaltrials.gov",
      "url": "https://clinicaltrials.gov/study/NCT05618145",
      "authors": "clinicaltrials.gov",
      "host": "clinicaltrials.gov"
    },
    {
      "number": 18,
      "title": "ACG Clinical Guideline: Primary Sclerosing Cholangitis",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25869391",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "Primary Sclerosing Cholangitis - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK537181",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Pathology Pearls Post 8: Primary Sclerosing Cholangitis (PSC) | AASLD",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/liver-fellow-network/core-series/pathology-pearls/pathology-pearls-post-8-primary-sclerosing",
      "authors": "www.aasld.org",
      "host": "www.aasld.org"
    },
    {
      "number": 21,
      "title": "Primary Sclerosing Cholangitis Management Tips and Tricks",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/primary-sclerosing-cholangitis-management-tips-and",
      "authors": "www.aasld.org",
      "host": "www.aasld.org"
    },
    {
      "number": 22,
      "title": "AASLD PRACTICE GUIDELINES Diagnosis and Management ...",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/sites/default/files/2022-07/Diagnosis%20and%20Management%20of%20Primary%20Sclerosing%20Cholangitis.pdf",
      "authors": "www.aasld.org",
      "host": "www.aasld.org"
    },
    {
      "number": 23,
      "title": "Why do people with primary sclerosing cholangitis require ...",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-people-primary-sclerosing-cholangitis-require-so",
      "authors": "www.aasld.org",
      "host": "www.aasld.org"
    },
    {
      "number": 24,
      "title": "New EASL Clinical Practice Guidelines on the ...",
      "detail": "easl.eu",
      "url": "https://easl.eu/news/easl-cpgs-autoimmune-hepatitis-2025",
      "authors": "easl.eu",
      "host": "easl.eu"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "[PDF] CENTER FOR DRUG EVALUATION AND RESEARCH",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/203214Orig1s018.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "or moderate hepatic impairment: half the total daily dosage recommended for patients with normal renal and hepatic function. (2, 8.7, 8.8) Dosage Adjustment x See the full prescribing information for dosage adjustments by indication for patients receiving CYP2C19 and/or CYP3A4 inhibitors; in patient",
      "score": 0.9687155904889254
    },
    {
      "number": 2,
      "title": "Pharmacokinetics in Patients with Impaired Hepatic Function",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/71311/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "function on __________ pharmacokinetics or pharmacodynamics (if known) is sufficiently small that no dosing adjustment is required. Contains Nonbinding Recommendations 12 For cases in which impaired hepatic function requires dosing adjustments, the appropriate information should be included. Special",
      "score": 0.9676305216946438
    },
    {
      "number": 3,
      "title": "Search Orphan Drug Designations and Approvals",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=821121",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "Decrease font size\nReturn font size to normal\nIncrease font size\nU.S. Department of Health and Human Services\nFDA, U.S. Food and Drug Administration\nSearch\n\n# Search Orphan Drug Designations and Approvals\n\nPrint\nShare\nE-mail\n\n|  |  |\n --- |\n| Generic Name: | Norucholic acid |\n| Date Designated: | 06",
      "score": 0.9640126783373968
    },
    {
      "number": 4,
      "title": "219488Orig1s000 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/219488Orig1s000MultidisciplineR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "Review and Evaluation Ctexli (chenodiol) 120 Version date: October 12, 2018 abnormalities, including intrahepatic cholestasis, primary biliary cirrhosis, or sclerosing cholangitis. The Warnings section of labeling states that safe use of the drug depends upon selection of patients without pre‐existi",
      "score": 0.9598255612909172
    },
    {
      "number": 5,
      "title": "220295Orig1s000 INTEGRATED REVIEW - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220295Orig1s000IntegratedR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "BID, twice daily; max, maximum; min, minimum; N, number of subjects; SD, standard deviation; UDCA, ursodeoxycholic acid Renal Impairment The Applicant proposed that no dose adjustment would be required for patients with renal impairment. The Applicant also states in the proposed Prescribing Informat",
      "score": 0.9594758956029816
    },
    {
      "number": 6,
      "title": "September 13, 2024 Gastrointestinal Drugs Advisory ...",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/183843/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "initiation of 18 treatment with OCA. Note here, Study 405 accepted 19 and OCA dispensing in the setting of previous or 20 concurrent UDCA as sufficient evidence for UDCA 21 treatment failure. 22 FDA GIDAC September 13 2024 A Matter of Record (301) 890-4188 172 Exclusion criteria describe variables u",
      "score": 0.9569675712083474
    },
    {
      "number": 7,
      "title": "Ocaliva® (Obeticholic Acid, OCA) ...",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/181819/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "days of UDCA in previous 365 days and ≥60 days of UDCA in previous 90 days – Intolerance – high ALP or BILI observed >90 days after a single episode of UDCA treatment lasting ≤90 days – Discontinued – (a) high ALP or BILI recorded ≥6 months after completing most recent UDCA course; or (b) any UDCA b",
      "score": 0.9544963067827851
    },
    {
      "number": 8,
      "title": "Office of Immunology and Inflammation - Division of Hepatology and Nutrition (DHN) | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/about-fda/cder-offices-and-divisions/office-immunology-and-inflammation-division-hepatology-and-nutrition-dhn",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "+ Liver failure associated with acetaminophen toxicity\n Acute-on-chronic liver failure (ACLF)\n Liver failure associated with parenteral nutrition\n Alpha 1 antitrypsin associated liver disease\n Lipodystrophy associated liver disease\n Bile Acid Malabsorption\n Cholestatic liver diseases\n  + Primary bil",
      "score": 0.9480351290383346
    },
    {
      "number": 9,
      "title": "EASL Clinical Practice Guidelines on sclerosing cholangitis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0168827822003269",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "2025, Gut     \n   ### ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease\n\n2024, Journal of Crohn's and Colitis     \n\nView all citing articles on Scopus\n\nAuthor names in bold designate shared co-first authorship\n\n☆\n\nClinical Practice Guideline Panel: Chair: Olivier Chazou",
      "score": 0.8874214752728133
    },
    {
      "number": 10,
      "title": "Surgical Treatment of Primary Sclerosing Cholangitis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/B9780323402323001175",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Patients with PSC have a 10% to 15% lifetime risk of developing cholangiocarcinoma (CCA). Five-year survival … 70% 5-year threshold needed",
      "score": 0.68420124
    },
    {
      "number": 11,
      "title": "Primary Sclerosing Cholangitis - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/primary-sclerosing-cholangitis",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "of primary sclerosing cholangitis (Fig. 3)[31][32]. A study evaluating MRCP in patients with primary sclerosing cholangitis demonstrated that MRCP has shown a sensitivity and specificity to depict primary sclerosing cholangitis of 85% to 88% and 92% to 97%, respectively . Diagnostic challenges includ",
      "score": 0.63234437
    },
    {
      "number": 12,
      "title": "Primary sclerosing cholangitis – a comprehensive review",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0168827817321967",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "2018, The Lancet  Show abstract Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterised by intrahepatic or extrahepatic stricturing, or both, with bile duct fibrosis. Inflammation and fibrosis of bile ducts and the liver are followed by impaired bile formation or fl",
      "score": 0.56460327
    },
    {
      "number": 13,
      "title": "Primary sclerosing cholangitis: A review and update",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6028044",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Skip to main content\n\nImage 1\n\nAn official website of the United States government\n\nHere's how you know\n\nHere's how you know\n\nImage 2\n\nOfficial websites use .gov\n\n A .gov website belongs to an official government organization in the United States.\n\nImage 3\n\nSecure .gov websites use HTTPS\n\n A lock ( ",
      "score": 0.9438709285548017
    },
    {
      "number": 14,
      "title": "Clinical guidelines for primary sclerosing cholangitis 2017",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8930933",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Skip to main content\n\nImage 1\n\nAn official website of the United States government\n\nHere's how you know\n\nHere's how you know\n\nImage 2\n\nOfficial websites use .gov\n\n A .gov website belongs to an official government organization in the United States.\n\nImage 3\n\nSecure .gov websites use HTTPS\n\n A lock ( ",
      "score": 0.9403155624641092
    },
    {
      "number": 15,
      "title": "The 2024 diagnostic criteria for primary sclerosing cholangitis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12450801",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "in Japan is considerably lower than in the West. To further delineate the present status of PSC in Japan, we conducted a nationwide survey of PSC in 2015 with the cooperation of the Japan Biliary Association and reported on the characteristics of 435 cases accumulated . The male-to-female ratio and ",
      "score": 0.9385644368573829
    },
    {
      "number": 16,
      "title": "Primary Sclerosing Cholangitis: Diagnosis, Management, and ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12897808",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Skip to main content\n\nImage 1\n\nAn official website of the United States government\n\nHere's how you know\n\nHere's how you know\n\nImage 2\n\nOfficial websites use .gov\n\n A .gov website belongs to an official government organization in the United States.\n\nImage 3\n\nSecure .gov websites use HTTPS\n\n A lock ( ",
      "score": 0.9359933439060514
    },
    {
      "number": 17,
      "title": "Study Details | NCT05618145 |  | ClinicalTrials.gov",
      "detail": "clinicaltrials.gov",
      "url": "https://clinicaltrials.gov/study/NCT05618145",
      "authors": "clinicaltrials.gov",
      "host": "clinicaltrials.gov",
      "snippet": "Image 1\n\nAn official website of the United States government\n\nHere’s how you know\n\nHere’s how you know\n\nImage 2\n\nOfficial websites use .gov\n\nA .gov website belongs to an official government organization in the United States.\n\nImage 3\n\nSecure .gov websites use HTTPS\n\nA lock ( ) or  means you’ve safel",
      "score": 0.9331187011425848
    },
    {
      "number": 18,
      "title": "ACG Clinical Guideline: Primary Sclerosing Cholangitis",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25869391",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "Primary sclerosing cholangitis is a chronic cholestatic liver disease that can shorten life and may require liver transplantation.",
      "score": 0.9293584542365309
    },
    {
      "number": 19,
      "title": "Primary Sclerosing Cholangitis - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK537181",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Warning:\nThe NCBI web site requires JavaScript to function.\nmore...\n\nU.S. flag\n\nAn official website of the United States government\n\nDot gov\n\nThe .gov means it's official.\n  \nFederal government websites often end in .gov or .mil. Before\nsharing sensitive information, make sure you're on a federal\ngo",
      "score": 0.9166278221973282
    },
    {
      "number": 20,
      "title": "Pathology Pearls Post 8: Primary Sclerosing Cholangitis (PSC) | AASLD",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/liver-fellow-network/core-series/pathology-pearls/pathology-pearls-post-8-primary-sclerosing",
      "authors": "www.aasld.org",
      "host": "www.aasld.org",
      "snippet": "| Lab Value | Result |\n --- |\n| AST | 70 U/L (10-50 U/L) |\n| ALT | 90 U/L (10-50 U/L) |\n| ALP | 247 U/L (35-130 U/L) |\n| Total Bilirubin | 3.3 mg/dL (0.0 – 1.0 mg/dL) |\n| HAV | Negative |\n| HBV | Negative |\n| HCV | Negative |\n| ANA | Positive |\n| Mitochondrial M2 Ab | Negative |\n| Smooth Muscle Ab |",
      "score": 0.5920305
    },
    {
      "number": 21,
      "title": "Primary Sclerosing Cholangitis Management Tips and Tricks",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/primary-sclerosing-cholangitis-management-tips-and",
      "authors": "www.aasld.org",
      "host": "www.aasld.org",
      "snippet": "Liver Transplantation\n\nGiven there is no disease-modifying treatment for PSC as discussed above, many will go on to develop decompensated liver disease requiring liver transplantation (LT). Indications for LT in patients with PSC include decompensated cirrhosis, hepatocellular carcinoma (HCC), high ",
      "score": 0.5356092
    },
    {
      "number": 22,
      "title": "AASLD PRACTICE GUIDELINES Diagnosis and Management ...",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/sites/default/files/2022-07/Diagnosis%20and%20Management%20of%20Primary%20Sclerosing%20Cholangitis.pdf",
      "authors": "www.aasld.org",
      "host": "www.aasld.org",
      "snippet": "143. Boberg KM, Rocca G, Egeland T, Bergquist A, Broome U, Caballeria L, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. HEPATOLOGY 2002;35:652-657.\n144. Majoie CB, Reeders JW, Sanders JB, Huibregtse K, Jansen PL. Primary sclerosin",
      "score": 0.5040288
    },
    {
      "number": 23,
      "title": "Why do people with primary sclerosing cholangitis require ...",
      "detail": "www.aasld.org",
      "url": "https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-people-primary-sclerosing-cholangitis-require-so",
      "authors": "www.aasld.org",
      "host": "www.aasld.org",
      "snippet": "## Gallbladder Cancer\n\nSimilar to CCA, patients with PSC are at a markedly increased risk for gallbladder cancer. Though the literature is varied, it is estimated that the prevalence of GBC in people with PSC is between 2.5% and 3.5%, with some studies reporting up to 21%. This increased risk is tho",
      "score": 0.40995342
    },
    {
      "number": 24,
      "title": "New EASL Clinical Practice Guidelines on the ...",
      "detail": "easl.eu",
      "url": "https://easl.eu/news/easl-cpgs-autoimmune-hepatitis-2025",
      "authors": "easl.eu",
      "host": "easl.eu",
      "snippet": "Therapeutically, the updated guidelines introduce Mycophenolate mofetil as a viable and safe first-line alternative to azathioprine. It is now recognised for its comparable or even superior efficacy and reduced rate of adverse events. However, clinicians are cautioned about its teratogenic risks, pa",
      "score": 0.5677694
    }
  ],
  "publishedAt": "2026-08-21T00:30:46.672523+00:00",
  "updatedAt": "2026-08-21T00:30:46.672523+00:00",
  "readingMinutes": 5,
  "slug": "primary-sclerosing-cholangitis"
}